New hope for ALS: Long-Term safety trial launches
NCT ID NCT07571174
First seen May 13, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This study looks at the long-term safety of a drug called LY4256984 for people with ALS, a progressive nerve disease. It is an extension of an earlier study and will follow 32 participants for about 96 weeks. The main goal is to see if the drug causes any serious side effects over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
McGill University Health Centre
Montreal, H4A 3J1, Canada
Contact
-
Sunnybrook Research Institute
Toronto, M4N 3M5, Canada
Contact
-
UZ Leuven
Leuven, 3000, Belgium
Contact
Conditions
Explore the condition pages connected to this study.